Torrent Pharmaceuticals Ltd. share price target

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company...

Torrent Pharma's (TRP) Q3FY22 performance was disappointing however we believe profitability/margins to normalize from FY23, aided by price hike in branded generic business and current cost escalation temporary. TRP's high exposure to branded generic business (~65-70% of total revenues) and chronic therapies provides comfort. The timely resolution of plants will pickup revenue growth in US and benefit operating leverage, going ahead. We expect 18% EPS CAGR over FY21-24E. We have cut our FY22E EPS by 6%...

TRP's 3QFY22 performance missed our estimate. The US Generics business remains the major drag on overall performance, with a lack of new approvals and a steep price erosion in the base business. Domestic Formulation (DF) remains in good stead, with healthy better-than-industry performance. The management intends to add medical representatives (MRs) to further strengthen the growth outlook in the DF segment. We reduce our FY22E/FY23E/FY24E EPS estimate by ~13%/7.5%/3.5% to factor in: a) a sharp reduction in the price realization of certain products...

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company...

...

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company...

TRP's 1QFY22 performance was largely in line with our estimates. Growth momentum in the Domestic Formulation (DF) business was offset by a muted showing in the US business and a higher tax rate. It continues to...

A strong growth track in top brands, measured new launches (including innovative launches) besides strong balance sheet and comfort on corporate governance front are some key attributes of Sanofi...

Q4 operational performance was in line with I-direct estimates whereas bottomline was better amid higher-than-expected other income and lower interest cost. Overhang pertaining to two US focused plants notwithstanding, Torrent continues to impress thanks to its robust margin profile that can be attributed to global portfolio that comprises ~60% branded generics. We expect a further improvement in this matrix, product rationalisation to further strengthen margins. The company's portfolio is finely balanced between India, Brazil, Germany and the US with India being...